Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
Haematologica|January 28, 2017
miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization studyAnne-Laure Gagez, Isabelle Duroux-Richard, Stéphane Leprêtre, et al.
British Journal of Haematology|March 25, 2016
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphomaBertrand Coiffier, Catherine Thieblemont, Sophie de Guibert, et al.
British Journal of Haematology|April 23, 2014
Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemiaEdouard Cornet, Cécile Tomowiak, Aline Tanguy-Schmidt, et al.
International Journal of Cancer|August 30, 2018
Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinomaBenoit Rousseau, Aude Guillemin, Christophe Duvoux, et al.
The Lancet. Haematology|December 22, 2015
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 studyJehan Dupuis, Franck Morschhauser, Hervé Ghesquières, et al.
The American Journal of Surgical Pathology|March 20, 2009
Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomasYenlin Huang, Anne Moreau, Jehan Dupuis, et al.
Blood|August 14, 2012
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphismsHervé Ghesquières, Guillaume Cartron, John Francis Seymour, et al.
Leukemia & Lymphoma|March 25, 2021
Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantationClarisse Cazelles, Karim Belhadj, Hélène Vellemans, et al.
Blood Advances|April 12, 2018
Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphomaMarie-Hélène Delfau-Larue, Axel van der Gucht, Jehan Dupuis, et al.
Blood|April 7, 2021
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final resultsMurielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, et al.
Pageof 9